Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study

Reporting results of cancer treatment

A. B. Miller, Barth Hoogstraten, M. Staquet et al. · Cancer · 1981 · 7.9K citations

Pharmacy, Oncology, Clinical Data Management +16

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

Steven A. Rosenberg, Michael T. Lotze, Linda Muul et al. · New England Journal of Medicine · 1987 · 2.8K citations

Pharmacy, Immunology, Oncology +14

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

Doris A. Morgan, Francis W. Ruscetti, Robert C. Gallo · Science · 1976 · 2.5K citations

Life Sciences, Cell Biology, Immunology +10

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Elizabeth A. Grimm, A Mazumder, H Z Zhang et al. · The Journal of Experimental Medicine · 1982 · 2.2K citations · Full text

Life Sciences, Immunology, Oncology +15

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

William H. West, Kurt W. Tauer, John R. Yannelli et al. · New England Journal of Medicine · 1987 · 1.2K citations

Medicine, Immunology, Oncology +16